ANNOUNCEMENT 09 Oct 2020

In October 2020, the Norwegian authorities introduced an export ban on formoterol and beclomethasone, formoterol, glycopyrronium and bromide as well as ciclesonide following the outbreak of COVID-19.

NUMBER OF INTERVENTIONS

1

  • 1 harmful
  • 0 neutral
  • 0 liberalising

SOURCE

The Norwegian Medicines Agency, Parallelleksport, meldeplikt og rasjonering av legemidler i forbindelse med covid-19: https://legemiddelverket.no/import-og-salg/import-og-grossistvirksomhet/parallelleksport-meldeplikt-og-rasjonering-i-forbindelse-med-covid-19
The Norwegian Medicines Agency, Liste over produkter med parallelleksportforbud (excel-fil, oppdatert 09.10.2020): https://legemiddelverket.no/Documents/Legemiddelmangel/Covid-19/Parallelleksportforbudlisten%2009102020.xlsx
The Norwegian Gazette, Regulation FOR-2020-03-06-239, Forskrift om tiltak for å sikre forsyningen av legemidler, medisinsk utstyr og personlig verneutstyr som følge av utbruddet av koronaviruset, issued on 6 March 2020: https://lovdata.no/dokument/LTI/forskrift/2020-03-06-239
The Norwegian Gazette, Regulation FOR-2020-03-06-239 with amendments: https://lovdata.no/dokument/SF/forskrift/2020-03-06-239

Inception date: 09 Oct 2020 | Removal date: 31 Dec 2020

Export ban

On 9 October 2020, the Norwegian Medicines Agency introduced an export ban on formoterol and beclomethasone, formoterol, glycopyrronium and bromide as well as ciclesonide following the outbreak of COVID-19. The export ban was introduced as it was considered a drug connected to the treatment of COVID-19. Prior to the introduction of an export ban, the pharmaceutical drug formoterol, glycopyrronium and bromide was subject to an export notification requirement, see related state act. The remaining pharmaceutical drugs were previously not subject to export restrictions by the Agency. 

Following the issuance on 6 March 2020 of Regulation FOR-2020-03-06-239 the Agency is empowered to impose export bans on these grounds. A number of export bans have already been introduced by the Norwegian Medicines Agency under Regulation FOR-2020-03-06-239.

Regulation FOR-2020-03-06-239 is in force until and including 31 December 2020. Unless revoked or withdrawn, the export ban is in force until said date. 

AFFECTED SECTORS

 

AFFECTED PRODUCTS